AACE Statement Regarding Public Review of Proposed Medicare CGM Coverage Changes
November 16, 2026
AACE Statement Regarding Public Review of Proposed Medicare CGM Coverage Changes

The American Association of Clinical Endocrinology (AACE) appreciates the Centers for Medicare & Medicaid Services (CMS) and the Durable Medical Equipment Medicare Administrative Contractors (DME MACs) for their continued work to ensure that Medicare coverage policies for diabetes technologies remain responsive to advances in clinical evidence and standards of care. AACE respectfully requests that CMS and the DME MACs provide an opportunity for public review and comment before finalizing any revisions to the continuous glucose monitoring (CGM) coverage criteria in Local Coverage Determination L33822.

Recent guidance from both AACE and the American Diabetes Association (ADA) reinforces the importance of evidence-based access to diabetes technology. AACE’s consensus statement, “Use of Diabetes Technology for Management of Adults with Diabetes,” reviews evidence supporting advanced diabetes technologies, including CGM, and provides practical, patient-centered guidance for health care professionals and adults with diabetes. The ADA’s first scientific statement focused exclusively on diabetes technology in primary care, “Diabetes Technology in the Primary Care Setting,” similarly provides evidence-informed recommendations for integrating CGM and other technologies into primary care. Developed by an interdisciplinary panel that included AACE representative Elias S. Siraj, MD, the ADA statement emphasizes that coverage, affordability, training, workflows, and data access must support equitable adoption. Together, these statements reflect broad clinical consensus that appropriate access to diabetes technology can improve glycemic management, reduce hypoglycemia, and enable more individualized, data-informed care.

CGM gives patients and clinicians consistent, actionable information about glucose patterns that can inform treatment decisions and support day-to-day self-management. Because most diabetes care is delivered in primary care, coverage policies should enable appropriately trained primary care teams—as well as endocrinology specialists—to prescribe, support, and use CGM effectively. Appropriate access to CGM is therefore an important component of high-quality diabetes care. Medicare coverage criteria should reflect current clinical evidence and the complementary expert guidance of AACE and the ADA so that people with diabetes who are most likely to benefit from CGM can access this technology.

AACE recognizes the significant work undertaken by CMS and the DME MAC medical directors to maintain and update coverage policies, often under substantial resource constraints. We appreciate these efforts and respectfully request that CMS and the DME MACs establish a transparent process that provides patients, clinicians, professional medical societies, and other interested stakeholders with an opportunity to review and comment on proposed changes to the CGM coverage criteria before those changes are finalized. Such a process would help ensure that any revisions reflect current evidence, specialty society guidance, expert consensus, and the practical needs of Medicare beneficiaries and the clinicians who care for them.

Our purpose in submitting this letter is to emphasize the importance of an open process through which relevant evidence and clinical expertise can be considered. A transparent review and comment period will help CMS and the DME MACs develop coverage criteria that promote appropriate patient access, improved health outcomes, and a higher quality of diabetes care.

AACE appreciates CMS’s continued attention to diabetes technology coverage. We welcome the opportunity to serve as a clinical resource, provide additional information, or participate in stakeholder discussions regarding potential revisions to Medicare’s CGM coverage criteria.

Sincerely, 

Dace Trence, MD MACE 

President American Association of Clinical Endocrinology

 

References 

  1. McGill JB, Donihi AC, Akturk HK, et al. American Association of Clinical Endocrinology Consensus Statement: Use of Diabetes Technology for Management of Adults with Diabetes. Endocrine Practice. Published online September 8, 2026. doi:10.1016/j.eprac.2026.06.011.
  2. Ebekozien O, Akturk HK, Aloi JA, et al. Diabetes Technology in the Primary Care Setting: An American Diabetes Association Scientific Statement. Diabetes, Obesity, and CardioMetabolic CARE. Published online September 28, 2026. doi:10.2337/doci26-0005.